Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men

NCT04593680 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Drug Interaction

Interventions

DRUG: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)

Sponsor

Thai Red Cross AIDS Research Centre